© 2020 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#Biktarvy
FDA Approves Gilead’s Single-Tablet HIV Regimen Biktarvy
Biktarvy (bictegravir + tenofovir alafenamide + emtricitabine) 101
Chart of Approved and Experimental HIV Medications

Switching to Biktarvy Is a Success for African Americans With HIV

Black study participants switched from a regimen with two nucleoside/nucleotide reverse transcriptase inhibitors plus one other HIV drug.

Switching HIV Regimen to Biktarvy Is Safe and Effective for the Long Term

Gilead Sciences presented findings from several studies of the single-tablet antiretroviral regimen at a recent scientific meeting.

Biktarvy Is Safe for Seniors

Pooled results from recent studies found a high rate of full viral suppression and no major safety concerns.

“Unprecedented” Transmission of Highly Drug-Resistant HIV in France

Researchers are surprised and concerned that a strain of HIV that is so broadly resistant to treatment even has the capacity to transmit.

Switching HIV Meds to New Tenofovir Tied to Weight Gain

People who switched from tenofovir disoproxil fumarate to tenofovir alafenamide gained weight regardless of other meds.

Switching HIV Meds to Biktarvy Is Safe, Effective Among Seniors

Pooled results from recent studies found a high rate of full viral suppression and no major safety concerns.

Even With New, Bone-Friendly HIV Regimens, More Bone Research Is Needed

This is especially the case for people globally who don’t have access to such newer regimens.
Emily Goodrow and Peter Staley

Drug Company Antitrust Trial Gets 2022 Court Date

Advocates claim Gilead and others unfairly limited competition for HIV combination pills.

What’s the Skinny on Bone Health for People With HIV?

Researchers have called for revised treatment guidelines to address the higher risk of fracture in the HIV population.
Descovy and Truvada

TAF Versus TDF: What’s the Difference?

Are You in for Integrase-Driven Weight Gain?

Researchers at George Washington University take a look.
Antiretroviral Drugs to Treat HIV Infection

U.S. Government Updates HIV Treatment Guidelines

The latest revision recognizes the importance of treatment as prevention.

Biktarvy Maintains High Efficacy for Three Years in Clinical Trials

The integrase inhibitor–based HIV regimen was compared with dolutegravir-based regimens.

Switching to New Tenofovir Linked to Rise in BMI and Cardiovascular Risk

This finding from a study of people switching from TDF to TAF for HIV treatment may also have implications for those on PrEP.

Who Gains Weight After Switching to Integrase Inhibitors?

Researchers at George Washington University take a look.

Switching Back to Older Tenofovir Improves Lipid Levels

The newer tenofovir formulation can raise cholesterol and triglyceride levels, but these changes are reversible.
Advertisement
Treatment News
Features